Devirs cream 7.5%, 15 g

As monotherapy or in combination with other dosage forms of ribavirin for oral and parenteral administration for the following diseases:

• infections of the skin and mucous membranes caused by Herpes simplex viruses of types 1 and 2, of various localization, incl. in the genital area;

• herpes zoster (as part of complex therapy).

Apply externally. The cream is applied to the affected areas of the skin and mucous membrane (previously washed and dried) in an even thin layer, rubbing slightly.

Apply 5 times / day until the symptoms of the disease disappear completely.

If there is no improvement within 8 days of using the drug, you should stop taking it and consult a doctor.

For best results, treatment should be started as early as possible when symptoms first appear.

When using DevirsЃ cream in combination with one of the dosage forms of ribavirin for oral administration or intravenous administration, the dose of the cream should be reduced.

Cream for external use 7.5% white or almost white, homogeneous.

100 g ribavirin 7.5 g

Excipients: glyceryl monostearate (glycerol monostearate 40-50) - 2 g, macrogol-6 cetostearyl alcohol ether (macrogol-6 cetostearyl ether) - 1.5 g, macrogol-25 cetostearyl alcohol ether (macrogol-25 cetostearyl ether) - 1.5 g cetostearyl alcohol - 5 g, liquid paraffin (vaseline oil) - 5 g, methyl parahydroxybenzoate (methyl hydroxybenzoate, methyl paraben, nipagin) - 0.1 g, propyl parahydroxybenzoate (propyl hydroxybenzoate, propyl paraben, 0.02 g, purified water - purified water - 0.02 g, purified water)

• Pregnancy;

• lactation period (breastfeeding);

• children and adolescents up to 18 years old;

• hypersensitivity to ribavirin and other components of the drug.

• The drug should be used with caution in renal failure, in women and men of reproductive age.

pharmachologic effect

Antiviral drug. Ribavirin triphosphate (RTF) is a potent inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase), viral RNA polymerase, and viral mRNA guanylyltransferase. Inhibition of the latter stops mRNA capping, which leads to a significant depletion of intracellular reserves of guanosine triphosphate and inhibition of viral RNA and protein synthesis. Ribavirin is also incorporated into the viral genome, causing lethal mutations, with a subsequent decrease in the pathogenicity of the virus. Ribavirin inhibits the replication of new virions, which reduces the viral load, selectively inhibits the synthesis of viral RNA, without suppressing the synthesis of RNA in normally functioning cells.

DNA viruses most sensitive to ribavirin are herpes simplex virus, adenoviruses, CMV, smallpox viruses, Marek's disease; RNA viruses - influenza A, B viruses, paramyxoviruses (parainfluenza, mumps, Njcastle disease), reoviruses, arenaviruses (Lassa fever virus, Bolivian hemorrhagic fever), Bunyaviruses (Rift Valley fever virus, Crimean-Congo haemorrhagic fever virus) (hemorrhagic fever virus with renal or pulmonary syndrome), oncogenic RNA viruses.

DNA viruses insensitive to ribavirin: Varicella zoster, pseudorabies virus, natural vaccinia; RNA viruses: enteroviruses, rhinoviruses, Semliki forest encephalitis virus.

Pharmacokinetics

When applied to the skin and topically, systemic absorption is minimal and practically insignificant.

Side effect

Allergic reactions: possible skin rash, urticaria, exanthema.

Others: hair loss, changes in the content of thyroid-stimulating hormone (TSH); extremely rare - symptoms of autoimmune diseases.

The observed effects, as a rule, are reversible, do not affect the effectiveness of treatment, and stop after the end of treatment.

Application during pregnancy and lactation

The use of the cream during pregnancy and lactation is contraindicated.

Women and men of reproductive age during treatment and within 7 months after the end of therapy should use effective contraceptives.

Application for impaired renal function

Use with extreme caution in patients with renal insufficiency.

Application in children

Contraindicated in children and adolescents under 18 years of age

special instructions

Do not use for the treatment of ophthalmic herpes, do not apply to the eye area.

Use with extreme caution in patients with renal insufficiency.

Overdose

Data on overdose of the drug DevirsЃ are not provided.

Drug interactions

Drug interaction of the drug DevirsЃ has not been identified.